Comparison of treatment strategies in early rheumatoid arthritis - A randomized trial

被引:371
作者
Goekoop-Ruiterman, Yvonne P. M.
de Vries-Bouwstra, Jeska K.
Allaart, Cornelia F.
van Zeben, Derkjen
Kerstens, Pit J. S. M.
Hazes, J. Mieke W.
Zwinderman, Aelko H.
Peeters, Andre J.
de Jonge-Bok, Johanna M.
Mallee, Constant
de Beus, Wim M.
de Sonnaville, Peter B. J.
Ewals, Jacques A. P. M.
Breedveld, Ferdinand C.
Dijkmans, Ben A. C.
机构
[1] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Jan Van Breemen Inst, Slotervaart Hosp, Amsterdam, Netherlands
[3] Amsterdam Med Ctr, Amsterdam, Netherlands
[4] Erasmus MC, Rotterdam, Netherlands
[5] Sint Francis Hosp, Rotterdam, Netherlands
[6] Reinier Graaf Gasthuis, Delft, Netherlands
[7] Groene Hart Hosp, Gouda, Netherlands
[8] Kennemer Gasthuis, Haarlem, Netherlands
[9] Med Ctr Haaglanden, Leidschendam, Netherlands
[10] Haga Hosp, The Hague, Netherlands
[11] Oosterschelde Hosp, Goes, Netherlands
关键词
D O I
10.7326/0003-4819-146-6-200703200-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In patients with early rheumatoid arthritis, initial combination therapies provide earlier clinical improvement and less progression of joint damage after 1 year compared with initial monotherapies (as demonstrated in the BeSt study). Objective: To evaluate whether the initial clinical and radiographic efficacy of combination therapies could be maintained during the second year of follow-up in patients with early rheumatoid arthritis. Design: Randomized, controlled clinical trial with blinded assessors. Setting: 18 peripheral and 2 university medical centers in the Netherlands. Patients: 508 patients with early active rheumatoid arthritis. Intervention: Sequential monotherapy (group 1), step-up combination therapy (group 2), initial combination therapy with tapered high-dose prednisone (group 3), or initial combination therapy with infliximab (group 4). Trimonthly treatment adjustments were made to achieve low disease activity. Measurements: Primary end points were functional ability (Health Assessment Questionnaire) and Sharp-van der Heijde score for radiographic joint damage. Results: Groups 3 and 4 had more rapid clinical improvement during the first year; all groups improved further to a mean functional ability score of 0.6 (overall, P = 0.257) and 42% were in remission (overall, P = 0.690) during the second year. Progression of joint damage remained better suppressed in groups 3 and 4 (median scores of 2.0, 2.0, 1.0, and 1.0 in groups 1, 2, 3, and 4, respectively [P= 0.004]). After 2 years, 33%, 31%, 36%, and 53% of patients in groups 1 through 4, respectively, were receiving single-drug therapy for initial treatment. There were no significant differences in toxicity. Limitations: Patients and physicians were aware of the allocated group, and the assessors were blinded. Conclusions: Currently available antirheumatic drugs can be highly effective in patients with early rheumatoid arthritis in a setting of tight disease control. Initial combination therapies seem to provide earlier clinical improvement and less progression of joint damage, but all treatment strategies eventually showed similar clinical improvements. In addition, combination therapy can be withdrawn successfully and less treatment adjustments are needed than with initial monotherapies.
引用
收藏
页码:406 / 415
页数:10
相关论文
共 27 条
[11]   Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis:: a double blind randomised placebo controlled trial [J].
Gerards, AH ;
Landewé, RBM ;
Prins, APA ;
Bruijn, GAW ;
Thè, HSG ;
Laan, RFJM ;
Dijkmans, BAC .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) :291-296
[12]  
Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI 10.1002/art.23364
[13]   Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial [J].
Grigor, C ;
Capell, H ;
Stirling, A ;
McMahon, AD ;
Lock, P ;
Vallance, R ;
Kincaid, W ;
Porter, D .
LANCET, 2004, 364 (9430) :263-269
[14]   Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [J].
Klareskog, L ;
van der Heijde, D ;
de Jager, JP ;
Gough, A ;
Kalden, J ;
Malaise, M ;
Mola, EM ;
Pavelka, K ;
Sany, J ;
Settas, L ;
Wajdula, J ;
Pedersen, R ;
Fatenejad, S ;
Sanda, M .
LANCET, 2004, 363 (9410) :675-681
[15]   Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate [J].
Maini, RN ;
Breedveld, FC ;
Kalden, JR ;
Smolen, JS ;
Furst, D ;
Weisman, MH ;
St Clair, EW ;
Keenan, GF ;
van der Heijde, D ;
Marsters, PA ;
Lipsky, PE .
ARTHRITIS AND RHEUMATISM, 2004, 50 (04) :1051-1065
[16]   Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis:: a randomised trial [J].
Möttönen, T ;
Hannonen, P ;
Leirisalo-Repo, M ;
Nissilä, M ;
Kautiainen, H ;
Korpela, M ;
Laasonen, L ;
Julkunen, H ;
Luukkainen, R ;
Vuori, K ;
Paimela, L ;
Blåfield, H ;
Hakala, M ;
Ilva, K ;
Yli-Kerttula, U ;
Puolakka, K ;
Järvinen, P ;
Hakola, M ;
Piirainen, H ;
Ahonen, J ;
Pälvimäki, I ;
Forsberg, S ;
Koota, K ;
Friman, C .
LANCET, 1999, 353 (9164) :1568-1573
[17]   Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications [J].
ODell, JR ;
Haire, CE ;
Erikson, N ;
Drymalski, W ;
Palmer, W ;
Eckhoff, PJ ;
Garwood, V ;
Maloley, P ;
Klassen, LW ;
Wees, S ;
Klein, H ;
Moore, GF .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (20) :1287-1291
[18]   Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985 [J].
Pincus, T ;
Sokka, T ;
Kautiainen, H .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1009-1019
[19]  
Prevoo MLL, 1996, BRIT J RHEUMATOL, V35, P1101
[20]   Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis -: A five-year randomized followup trial [J].
Puolakka, K ;
Kautiainen, H ;
Möttönen, T ;
Hannonen, P ;
Korpela, M ;
Julkunen, H ;
Luukkainen, R ;
Vuori, K ;
Paimela, L ;
Blåfield, H ;
Hakala, M ;
Leirisalo-Repo, M .
ARTHRITIS AND RHEUMATISM, 2004, 50 (01) :55-62